A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women

doi:10.1016/S0029-7844(97)00704-7

Obstetrics & Gynecology

Volume 91, Issue 3, March 1998, Pages 432-436

https://doi.org/10.1016/S0029-7844(97)00704-7 Get rights and content

Abstract

Objective: To investigate the effects of oral 17β-estradiol (E2) -dydrogesterone on fasting plasma homocysteine concentrations in healthy postmenopausal women.

Methods: We studied 27 postmenopausal women who were assigned randomly to either a treatment group (n = 14) or a control group (n = 13). During the first 12 months of the study, treatment consisted of oral E2, 1 mg daily, combined sequentially with dydrogesterone 5 or 10 mg (14 days per 28-day treatment cycle). Thereafter, women were treated with oral E2,2 mg daily, combined sequentially with dydrogesterone, 10 mg daily (14 days per 28-day treatment cycle) for a period of 3 months. The control group received no treatment. Fasting plasma total homocysteine concentrations were determined at baseline and 3, 12, and 15 months after study entry.

Results: At baseline, plasma homocysteine levels did not differ between the groups. After 15 months of hormone treatment mean plasma homocysteine concentration was lowered by 12.6% compared with baseline (P < .001; analysis of variance for repeated measures). Plasma homocysteine levels were not altered in the control group. The interaction between treatment and time for homocysteine levels was significantly different between the groups (P < .001; analysis of variance for repeated measures). The decrease in plasma homocysteine levels correlated inversely with the increase in serum E2 levels after 3 and 12 months of hormone treatment (r = −.54, P < .05 and r = −.56, P < .05, respectively).

Conclusion: Plasma fasting homocysteine concentrations are lowered by E2-dydrogesterone therapy in postmenopausal women.

References (23)

A. Pines et al.
Hormone replacement therapy and cardioprotection: Basic concepts and clinical considerations
Eur J Obstet Gynecol Reprod Biol
(1997)
M. Den Heijer et al.
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
Lancet
(1995)
L.E. Brattstrom et al.
Folic acid responsive postmenopausal homocysteinemia
Metabolism
(1985)
J.B. Ubbink et al.
Rapid high performance liquid chromatographic assay for total homocysteine levels in human serum
J Chromatogr
(1991)
M.J. Van der Mooren et al.
The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women
Fertil Steril
(1997)
M.H. Kim et al.
Cortisol and estradiol: Non-genetic factors for hyperhomocyst(e)inemia
Metabolism
(1997)
M.M. Rees et al.
Homocystememia: Association of a metabolic disorder with vascular disease and thrombosis
Thromb Res
(1993)
T. Bienvenu et al.
Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters
Thromb Res
(1993)
C.J. Boushey et al.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
JAMA
(1995)
K. Robinson et al.
Hyperhomocystememia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease
Circulation
(1995)

M.J. Stampfer et al.

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

JAMA

(1992)

Cited by (113)

Epigenetics and migraine
2017, Neuropsychiatric Disorders and Epigenetics
Migraine is a neurological disorder that manifests as a debilitating headache associated with an altered sensory perception. It has classically been attributed to multifactorial etiologies, with genetic components and environmental interactions considered to be major influences. The neuropeptide calcitonin gene–related peptide (CGRP), flavoenzyme 5,10-methylenetetrahydrofolate reductase (MTHFR), and estrogen play key roles in migraine. In addition, receptor activity modifying protein 1 (RAMP1) is the primary receptor subunit of CGRP and plays a critical role in migraine. However, variations in the RAMP1 gene have not been found to be associated with migraine. Nevertheless, vitamins B₆, B₉, and B₁₂ and MTHFR play vital roles in both methionine biosynthesis and DNA methylation. Higher levels of homocysteine are attributed to lower levels of estrogen among migraine patients. This chapter elucidates the genetic and epigenetic roles of CGRP, MTHFR, and estrogen in the pathophysiology of migraine.
Plasma homocysteine, dietary B vitamins, betaine, and choline andrisk of peripheral artery disease
2014, Atherosclerosis
Few studies have examined the roles of homocysteine and related nutrients in the development of peripheral artery disease (PAD). We examined the associations between plasma homocysteine, dietary B vitamins, betaine, choline, and supplemental folic acid use and incidence of PAD.
We used two cohort studies of 72,348 women in the Nurses' Health Study (NHS, 1990–2010) and 44,504 men in the Health Professionals Follow-up Study (HPFS, 1986–2010). We measured plasma homocysteine in nested matched case–control studies of clinically recognized PAD within both cohorts, including 143 PAD cases and 424 controls within the NHS (1990–2010) and 143 PAD cases and 428 controls within the HPFS (1994–2008). We examined the association between diet and risk of incident PAD in the cohorts using a food frequency questionnaire and 790 cases of PAD over 3.1 million person-years of follow-up.
Higher homocysteine levels were positively associated with risk of PAD in men (adjusted IRR 2.17; 95% CI, 1.08–4.38 for tertile 3 vs. 1). There was no evidence of an association in women (adjusted IRR 1.14; 95% CI, 0.61–2.12). Similarly, higher folate intake, including supplements, was inversely associated with risk of PAD in men (adjusted HR 0.90; 95% CI, 0.82–0.98 for each 250 μg increase) but not women (HR 1.01, 95% CI, 0.88–1.15). Intakes of the other B vitamins, betaine, and choline were not consistently associated with risk of PAD in men or women.
Homocysteine levels were positively associated and dietary folate intake was inversely associated with risk of PAD in men but not in women.
The female runner: Gender specifics
2010, Clinics in Sports Medicine
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: A randomised controlled trial
2009, European Journal of Obstetrics and Gynecology and Reproductive Biology
Citation Excerpt :
In Europe oestradiol containing hormone combinations are prescribed more frequently. Oestradiol plus dydrogesterone is an oral HT with beneficial effects on various cardiovascular risk markers [8,9]. The dosage of MPA used in this study is higher than in the HERS and WHI study, because we treated younger early postmenopausal women.
To compare the short-term effects of two oral continuous combined oestrogen–progestogen treatment regimens on blood concentrations of several cardiovascular risk markers in healthy postmenopausal women.
In a 12-week randomised controlled study, 48 healthy non-hysterectomised postmenopausal women, aged 41–58 years, received either no treatment (control group; n = 16), or daily oral continuous combined treatment with 1 mg micronised 17β-oestradiol plus 5 mg dydrogesterone (E/D group; n = 18) or 0.625 mg conjugated equine oestrogens plus 5 mg medroxyprogesterone acetate (CEE/MPA group; n = 14).
Fasting blood sampling was performed at baseline and after 12 weeks of follow-up.
Compared with the control group, 12-week treatment with E/D or CEE/MPA reduced fibrinogen (−7.7%, p = 0.004 and −3.3%, p = 0.083, respectively), factor VII-act (−8.7%, p = 0.14 and −9.7%, p = 0.06, respectively), homocysteine (−20.5%, p = 0.02 and −26.7%, p = 0.005, respectively), and IGF-1 (−27.9%, p < 0.001 and −18.1%, p = 0.002, respectively), but increased factor VII-ag (+10.1%, p = 0.03 and +4.4%, p = 0.46, respectively), endothelin-1 (+15.2%, p = 0.12 and +20.0%, p = 0.13, respectively) and C-reactive protein (+88.8%, p = 0.18 and +71.0%, p = 0.44, respectively). Fibrinolytic factors were not affected by either hormone therapy (HT).
Short-term oral continuous combined therapy with oestradiol/dydrogesterone and conjugated equine oestrogens/medroxyprogesterone acetate had comparable effects on the investigated cardiovascular risk markers.
Plasma homocysteine levels in cycling, pregnant, and spayed bitches
2008, Animal Reproduction Science
The aim of this study was to evaluate the physiological range of homocysteine (Hcy) exhibited by bitches during the follicular (pro-oestrus), luteal (dioestrus) and anoestrus phases of cycling animals, and in pregnant and spayed bitches. The lowest concentrations of Hcy were observed during dioestrus (3.2 ± 1.27 μmol/L) and in pregnant bitches (3.9 ± 1.72 μmol/L), and the highest concentrations during anoestrus (7.8 ± 0.6 μmol/L) and in spayed bitches (12.1 ± 5.16 μmol/L).
A comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: A randomized, placebo-controlled study
2007, European Journal of Obstetrics and Gynecology and Reproductive Biology
Citation Excerpt :
Unfortunately, the majority of the studies supporting a reduction in serum Hcy levels after HRT did not focus on the plausible effects of administration routes and/or regimen types. However, the studies that compared the oral with the transdermal HRT administration routes reported a reduction using both routes [15–19,33]. On the contrary, the current, placebo-controlled study was not able to show any effects using both routes.
The objective was to determine the effects of transdermal and oral hormone replacement therapies on plasma total homocysteine levels in postmenopausal women.
One hundred and ten postmenopausal patients were enrolled in the study. Participants were randomized into three groups: in Group A (n = 31) oral continuous combined therapy and in Group B (n = 30) transdermal sequential hormone replacement therapy were given for 6 months. A placebo was administered orally to the control group (Group C, n = 30). Serum homocysteine levels were studied prior to and after 6 months of treatment in all groups.
There were no statistical significant differences in mean serum homocysteine levels among the groups prior to the study. The mean homocysteine levels after 6 months in Groups A–C were also similar.
Serum homocysteine levels alter with neither oral continuous nor sequential transdermal hormone replacement therapy.

View all citing articles on Scopus

View full text

A randomized controlled study of the effects of 17Beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women

Abstract

Eur J Obstet Gynecol Reprod Biol

Lancet

Metabolism

J Chromatogr

Fertil Steril

Metabolism

Thromb Res

Thromb Res

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

JAMA

Hyperhomocystememia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease

Circulation

A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians

JAMA